anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies (ADA) in the studies described below with incidence of ADA in other studies, including those of ADCETRIS or of other brentuximab vedotin products.

Among adult patients with relapsed or refractory cHL and relapsed or refractory systemic ALCL in Studies 1 and 2 [see Clinical Studies (14.1) and (14.3)], treatment-emergent ADA (or anti-brentuximab vedotin antibodies) developed in 37% (58/156) of patients who were tested for anti-brentuximab vedotin antibodies. Approximately 7% of patients in these trials developed persistently positive antibodies (positive test at more than 2 time points) and 30% developed transiently positive antibodies (positive at 1 or 2 post-baseline time points). Two of the patients (1%) with persistently positive antibodies experienced adverse reactions consistent with infusion reactions that led to discontinuation of treatment. Overall, a higher incidence of infusion related reactions was observed in patients who developed persistently positive antibodies. The incidence of treatment-emergent neutralizing antibodies against brentuximab vedotin was 62% (36/58). The effect of anti-brentuximab vedotin antibodies on efficacy is not known.

Among pediatric patients with previously untreated high risk cHL in Study 7 [see Clinical Studies (14.1)], of the 26 patients tested, none of the patients tested positive for anti-brentuximab vedotin antibodies.
All subjects will be investigated by high-resolution anorectal manometry. At the beginning the anorectal cather will be used to record conventional parameters and after that 3D high-definition anorectal manometric catheter will be inserted in order to measure conventional parameters and 3D picture of anorectum.
FIELD: technology of preparing and purification of shilagit. SUBSTANCE: shilagit-like substances are prepared from the natural raw by grinding and extraction with water at 40-50 C, filtration, evaporation up to concentration 27-33% , repeated filtration and drying. After repeated filtration solution can be subjected for ultrafiltration up to preparing of the end product with mol. mass 40 kDa, not more. Ash content of products is by 17-35% lower as compared with that in product preparing by known methods. EFFECT: improved method of shilagit-like substance preparing. 1 tbl
Experts from scientific, ethical, and economic perspectives have stressed the need for evidence-based mental health treatments, i.e., 'treatment based on the best available science or research evidence.' While several evidence-based treatments have been developed, there is a critical shortage of clinicians trained in these approaches. NIMH has identified the dissemination and implementation of evidence-based interventions as a top priority. One of the best studied evidence-based psychological treatments is interpersonal psychotherapy (IPT). Several decades of clinical trials have documented the efficacy of IPT across a diversity of mental health disorders and demonstrated the feasibility of teaching IPT to therapists from a range of backgrounds. Unfortunately, relatively few clinicians have been trained in IPT; as a result, few patients benefit from this treatment. The long term objective of this project is to meaningfully increase the number of mental health professionals trained in IPT by developing a set of internet training tools which will facilitate widespread dissemination of this training. In contrast to other evidence based therapies (e.g., cognitive behavior therapy), for which new training technologies have now been extensively studied, limited efforts to disseminate IPT to date have relied on traditional approaches (e.g., workshops), which are not cost-effective or easily accessible. In phase we will develop a prototype IPT training program and test its feasibility and efficacy. The training will comprise three components: a) An on-line, interactive, multi-media tutorial presenting the principles, stages, and techniques of IPT, b) Live, applied clinical training using videoconferencing in order to hone and evaluate trainees' clinical skills in IPT, and c) An on-line portal (IPT Case Tracker) to help therapists maintain adherence and facilitate integration of IPT into their ongoing clinical practice. Twenty-four clinicians from various mental health disciplines without prior IPT training will be recruited. Trainees will be tested on their knowledge of IPT concepts before and after completing the tutorial. Following completion of the tutorial, trainees will conduct an IPT session with a standardized patient while being observed by the trainer in real time using videoconferencing, in order to transfer knowledge into applied skills. After completing training, trainees will utilize the internet portal to help incorporate IPT into their clinical practice. The interactive portal will prompt trainees with brief reminders before IPT sessions and will administer a post-session checklist to help maintain and to monitor ongoing adherence to IPT. Feasibility and user satisfaction for the tutorial, live training and internet portal will be evaluated.
The present invention relates to a motion sensor and camera-based augmented reality system for dementia prevention and rehabilitation training for mild cognitive impairment. Cognitive rehabilitation training is performed by making a card game linked with a motion sensor. Among the images received from the camera, only the hand is processed to be visible. It interacts with the motion sensor to realize a mixed reality that combines virtual reality and augmented reality. So, immersion can be increased. Focusing on the cognitive rehabilitation of the elderly, familiar card images are applied to reduce resistance to rehabilitation training. The system includes: a cam module; a motion detection module; a display module; and a control module.
Anaphylaxis has been reported to occur after administration of XOLAIR in premarketing clinical trials and in postmarketing spontaneous reports [see Boxed Warning and Adverse Reactions (6.2)]. Signs and symptoms in these reported cases have included bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue. Some of these events have been life-threatening. In premarketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3507 (0.1%) patients. Anaphylaxis occurred with the first dose of XOLAIR in two patients and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient.

A case-control study in asthma patients showed that, among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis [see Adverse Reactions (6.1)].

In postmarketing spontaneous reports, the frequency of anaphylaxis attributed to XOLAIR use was estimated to be at least 0.2% of patients based on an estimated exposure of about 57,300 patients from June 2003 through December 2006. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond one year after beginning regularly scheduled treatment. Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of XOLAIR, with additional cases occurring sporadically beyond the third dose.

Initiate XOLAIR only in a healthcare setting equipped to manage anaphylaxis, which can be life-threatening. Observe patients closely for an appropriate period of time after administration of XOLAIR, taking into account the time to onset of anaphylaxis seen in premarketing clinical trials and postmarketing spontaneous reports [see Adverse Reactions (6.1, 6.2)]. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs or symptoms occur.

Once XOLAIR therapy has been established, administration of XOLAIR prefilled syringe or autoinjector outside of a healthcare setting by a patient or a caregiver may be appropriate for selected patients. Patient selection, determined by the healthcare provider in consultation with the patient, should take into account the pattern of anaphylaxis events seen in premarketing clinical trials and postmarketing spontaneous reports, as well as individual patient risk factors (e.g., prior history of anaphylaxis), ability to recognize signs and symptoms of anaphylaxis, and ability to perform subcutaneous injections with XOLAIR prefilled syringe or autoinjector with proper technique according to the prescribed dosing regimen and Instructions for Use [see Dosage and Administration (2.6), Adverse Reactions (6.1, 6.2)].

Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction [see Contraindications (4)].
Participants will complete 8 weekly therapy sessions focused on improving pain. A multicomponent CBT-P (Cognitive Behavioral Therapy for Pain) protocol will involve: pain education, relaxation, activity pacing, and cognitive restructuring.
The present invention relates to gliocladin and an application method thereof, which belongs to the technical field of medical antibiotics. The gliocladin is obtained by production strains through conventional liquid or solid fermentation and metabolite extraction, the production strains are gliocladium roseum Gr87 which is preserved in China Committee of Culture Collection for Microorganisms (CCCCM) on October 9, 2002 with a preservation number of CGMCC No. 0807; the gliocladin has a molecular formula of C21H16N6O2 with the molecular weight of 384. The present invention also provides the application method of the gliocladin used for preparing antibiotics for preventing and treating Sh. sonnei dysentery bacillus, mycobacterium tuberculosis, pseudomonas aeruginosa, Sh. dysenteriae dysentery bacillus, staphylococcus aureus, colibacillus, streptococcus hemolyticus, Shigelladysentery bacillus, etc.
PROBLEM TO BE SOLVED: To obtain a monomeric protein effective for preventing or treating chondropathy/osteopathy. SOLUTION: This monomeric protein has such an amine acid sequence that cysteine involved in the dimer formation for a protein belonging to TGF-β- superfamily is substituted with another amino acid, and has double differentiation-inducing activity on osteoblastic cell line compared to the corresponding dimeric protein. The amino acid to be substituted is e.g. serine, threonine, alanine, valine, being esp. pref. alanine. This monomeric protein is produced by using Escherichia coli, yeast, insect cells or mammalian cells transformed with a plasmid containing a DNA sequence capable of expressing this monomeric protein.
UNLABELLED: The hospital environmental microbiome, which can affect patients' and healthcare workers' health, is highly variable and the drivers of this variability are not well understood. In this study, we collected 37 surface samples from the neonatal intensive care unit (NICU) in an inpatient hospital before and after the operation began. Additionally, healthcare workers collected 160 surface samples from five additional areas of the hospital. All samples were analyzed using 16S rRNA gene amplicon sequencing, and the samples collected by healthcare workers were cultured. The NICU samples exhibited similar alpha and beta diversities before and after opening, which indicated that the microbiome there was stable over time. Conversely, the diversities of samples taken after opening varied widely by area. Principal coordinate analysis (PCoA) showed the samples clustered into two distinct groups: high alpha diversity [the pediatric intensive care unit (PICU), pathology lab, and microbiology lab] and low alpha diversity [the NICU, pediatric surgery ward, and infection prevention and control (IPAC) office]. Least absolute shrinkage and selection operator (LASSO) classification models identified 156 informative amplicon sequence variants (ASVs) for predicting the sample's area of origin. The testing accuracy ranged from 86.37% to 100%, which outperformed linear and radial support vector machine (SVM) and random forest models. ASVs of genera that contain emerging pathogens were identified in these models. Culture experiments had identified viable species among the samples, including potential antibiotic-resistant bacteria. Though area type differences were not noted in the culture data, the prevalences and relative abundances of genera detected positively correlated with 16S sequencing data. This study brings to light the microbial community temporal and spatial variation within the hospital and the importance of pathogenic and commensal bacteria to understanding dispersal patterns for infection control.
IMPORTANCE: We sampled surface samples from a newly built inpatient hospital in multiple areas, including areas accessed by only healthcare workers. Our analysis of the neonatal intensive care unit (NICU) showed that the microbiome was stable before and after the operation began, possibly due to access restrictions. Of the high-touch samples taken after opening, areas with high diversity had more potential external seeds (long-term patients and clinical samples), and areas with low diversity and had fewer (short-term or newborn patients). Classification models performed at high accuracy and identified biomarkers that could be used for more targeted surveillance and infection control. Though culturing data yielded viability and antibiotic-resistance information, it disproportionately detected the presence of genera relative to 16S data. This difference reinforces the utility of 16S sequencing in profiling hospital microbiomes. By examining the microbiome over time and in multiple areas, we identified potential drivers of the microbial variation within a hospital.
Use of ritonavir, saquinavir or their salts as proteasome modifying drugs is new. Use of at least one human immunodeficiency virus (HIV) protease inhibitor (I) selected from ritonavir, saquinavir and their salts, in combination with a pharmaceutical carrier, is claimed for the preparation of a medicament for modulating the proteasome. An independent claim is included for a method for screening for HIV protease inhibitors, involving testing the compounds for their ability to modulate proteasome activity. ACTIVITY : Antiinflammatory; immunoregulatory; antirheumatic; antiarthritic; antidiabetic; antipsoriatic; antiviral; cytostatic. Oral treatment with saquinavir at 4 mg per day for 7 days inhibited mouse paw edema, induced by injection of lymphocytic chorio-meningitis virus, by 73%. MECHANISM OF ACTION : HIV protease inhibitor; proteasome modulator. Proteasome is the central enzymatic protein degradation system, present in cytosol and cell nuclei and having multiple peptidase activity. (I) especially inhibit the chymotrypsin-like activity and increase the trypsin-like activity of proteasome; modify the presentation of antigens at the cell surface (in combination with the major histocompatibility complex class 1); and inhibit or modify the activation of cytotoxic CD8+> T lymphocytes.
Complementing other efforts to increase access to COVID-19 testing in the United States, the federal government recently announced the purchase of 500,000,000 at home COVID-19 to be distributed for free "to Americans that want them". A central logistical element in matching supply with demand will be a website, on which people will register their interest in getting tests delivered to their home address. However, it is still unclear how supply will be matched with demand. Three main candidate options are first come, first served (FCFS), in which people are sent tests in the order in which they make requests; a random draw, such as a lottery; or a combination of a random draw with a guaranteed reserved amount for more disadvantaged populations. FCFS is a widely known and practiced rationing principle, but it has shown to exacerbate inequities in, for example, the allocation of vaccine appointments. Random draws can mitigate this impact, but, in the present context, might be insufficiently sensitive to the fact that not everyone has internet access, and that the need for testing is greater among more disadvantaged communities. Combining a lottery with a disadvantage reserve system using measures such as the CDC's Social Vulnerability Index is a practical way of promoting equity, and it was already used by the majority of US states in allocating vaccines. The main objective of this study is to assess public support for each of these three allocation plans and describe differences by demographic characteristics. Investigators will also assess public attitudes toward specific details of these allocation plans. The study, which is expected to take approximately 5 minutes to complete, will be administered as part of an omnibus online survey.
PURPOSE:To prepare the titled dermatic medicine, having suppressed skin irritation caused by the medicine or the cosmetic components without affecting the preparation stability of the agent, by compounding pantethine to a topicum or a skin cosmetic base. CONSTITUTION:A skin topicum, a cosmetic, and other local topicum for applying to the cuticle, is compounded with pref. 1-20% of pantethine of formula. The compound of formula exhibits extremely outstanding effect as an agent for suppressing the skin irritation of a local topicum. It is extremely stable in an aqueous solution, and scarcely reactive with the drug component and other ingredients in a physicochemical sense. Accordingly, the addition of said compound enables the use of a drug component which cannot hitherto be used as a practical topicum owing to the irritation, the combined use of various drug components, and the preparation of topicum having composite activities. It also enables the free application of desired drugs even to children and women having sensible skin or to the patients sensible to irritation.
BACKGROUND: Beckwith-Wiedemann syndrome (BWS) is an overgrowth disorder that exhibits etiologic genomic imprinting characterized by molecular heterogeneity and phenotypic variability. Associations with localized developmental dysplastic chondromatous lesions and cortical neuronal heterotopias have not previously been described.
CASE PRESENTATION: A 33-week gestational age female had an omphalocele and intractable hypoglycemia at birth. The placenta demonstrated placental mesenchymal dysplasia. Detection of hypermethylation of IC1 and hypomethylation of IC2 confirmed Beckwith-Wiedemann syndrome, most likely due to uniparental disomy. Additional findings included right mid-tibial and right 5-8th developmental dysplastic chondromatous lesions, absent corpus callosum and numerous right-sided cortical neuronal heterotopias, right hemihypertrophy, multiple cystic hepatic mesenchymal hamartomas and hepatic infantile hemangiomas, nisidioblastosis and cystic pancreatic lesions. The infant died with multi-organ failure and anasarca at 7 weeks of life.
CONCLUSION: Beckwith-Wiedemann syndrome anomalies may include multifocal developmental dysplastic chondromatous lesions and cerebral neuronal heterotopias, lateralized, and corpus callosum aplasia.
Tramadol hydrochloride extended-release tablets were studied in four 12-week, randomized, double-blind, controlled studies in patients with moderate to severe pain due to osteoarthritis. Efficacy was demonstrated in one double-blind, placebo-controlled, randomized withdrawal design study. In this study, patients who experienced a reduction of pain and were able to tolerate tramadol hydrochloride extended-release tablets during an open-label titration period, were then randomized to tramadol hydrochloride extended-release tablets or to placebo for 12 weeks. Sixty-five percent of patients were able to successfully titrate onto tramadol hydrochloride extended-release tablets. After a washout, patients randomized to tramadol hydrochloride extended-release tablets were titrated to 200 mg or 300 mg of tramadol hydrochloride extended-release tablets based on tolerability and remained on that dose for the following 12-week period. Approximately 24% of patients discontinued during the randomized period of the study, with more patients discontinuing from the tramadol hydrochloride extended-release tablets arm than the placebo arm due to adverse events (10% vs. 5%, respectively) and more patients discontinuing from the placebo arm than the tramadol hydrochloride extended-release tablets arm due to lack of efficacy (10% vs. 8%, respectively). Patients treated with tramadol hydrochloride extended-release tablets demonstrated a greater improvement in pain intensity, measured on an 11-point numerical rating scale, at the end of treatment compared to patients randomized to placebo. Figure 3 shows the fraction of patients achieving various degree of improvement in pain from baseline to the end of treatment (week 12). The figure is cumulative, so that patients whose change from baseline is, for example, 50%, are also included at every level of improvement below 50%. Patients who did not complete the study were assigned 0% improvement.

  
Figure 3. Proportion of Patients Achieving Various Levels of Pain Relief as Measured by 12-Week Pain Intensity.
Cardiometabolic diseases usually do not produce significant mortality and morbidity until adulthood. There is clear evidence, however, that these diseases have their origins in childhood and adolescence. With the rising incidence of obesity associated with poorer eating and less physical activity in children and adolescents it is important that the investigators study these diseases early in their course if the investigators are to prevent future cardiometabolic disease. While obesity clearly increases cardiometabolic risk, not all obese subjects are at increased risk; approximately 25-30% of obese adults and adolescents are metabolically healthy. The complement system is key physiological component in controlling inflammation and recent studies have indicated complement plays an important role in increasing obesity and cardiometabolic risk. Adults with proven cardiometabolic disease or at future risk for cardiometabolic disease have increased levels of the complement components C3, C3a-desArg, and C4 compared to healthy, not at risk, control subjects, independent of obesity. Increased C3 or C3a-desArg levels in adolescents are associated with increased cardiometabolic risk independent of obesity. Two specific single nucleotide polymorphisms (SNPs) in the intron for C3, rs11569562 and rs2250656, both with A\>G polymorphisms, are associated with increased serum C3 levels, and increases in a variety of cardiovascular risk factors. No one has investigated how C3 polymorphisms affect risk factors in adolescents. The C4 gene has significant copy number variation and increased copy number is associated with increased C4 levels. The relationship of C4 gene copy number to cardiometabolic risk has not been studied in adults or adolescents. The short-term objectives of this study are to explore differences in cardiometabolic risk factors in overweight and obese adolescents with C3 polymorphisms and also to explore how C4 gene copy number variation affects risk factors. The investigators overall hypothesis is that variations in C3 polymorphisms, C4 gene copy number or both will have significant impact on cardiometabolic health in overweight and obese adolescents. Both traditional and nontraditional cardiometabolic risk markers, including measures of body habitus, blood pressure, lipids, vascular function, insulin secretion and sensitivity, inflammation, and clotting will be investigated in 100 overweight and obese adolescents. The investigators proposed study will help us understand the role of complement and its genetics in the development of cardiometabolic risk and in potentially developing genetic biomarkers for adolescents at increased risk.